Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.

de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP.

Haematologica. 2019 Nov 7. pii: haematol.2019.227272. doi: 10.3324/haematol.2019.227272. [Epub ahead of print]

2.

Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016.

Posthuma HLA, Zijlstra JM, Visser O, Lugtenburg PJ, Kersten MJ, Dinmohamed AG.

Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16290. [Epub ahead of print]

PMID:
31682006
3.

Tailoring the amount of treatment information to cancer patients' and survivors' preferences: Effects on patient-reported outcomes.

Lehmann V, Labrie NHM, van Weert JCM, van Dulmen S, de Haes HJCJM, Kersten MJ, Pieterse AH, Smets EMA.

Patient Educ Couns. 2019 Sep 26. pii: S0738-3991(19)30432-X. doi: 10.1016/j.pec.2019.09.024. [Epub ahead of print]

PMID:
31585818
4.

Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data.

van Vulpen JK, Sweegers MG, Peeters PHM, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Schmidt ME, Ulrich CM, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, May AM, Buffart LM.

Med Sci Sports Exerc. 2019 Sep 12. doi: 10.1249/MSS.0000000000002154. [Epub ahead of print]

PMID:
31524827
5.

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.

J Clin Oncol. 2019 Sep 9:JCO1900743. doi: 10.1200/JCO.19.00743. [Epub ahead of print]

PMID:
31498031
6.

Effects and moderators of exercise on sleep in adults with cancer: Individual patient data and aggregated meta-analyses.

Bernard P, Savard J, Steindorf K, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvao DA, Chinapaw MJ, Stuiver MM, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Bohus M, Thorsen L, Schmidt ME, Ulrich CM, Sonke GS, van Harten W, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, Buffart LM.

J Psychosom Res. 2019 Sep;124:109746. doi: 10.1016/j.jpsychores.2019.109746. Epub 2019 Jun 23. Review.

PMID:
31443811
7.

Provider caring and structuring treatment information to improve cancer patients' recall: Does it help?

Lehmann V, Labrie NHM, van Weert JCM, van Dulmen S, de Haes HJCJM, Kersten MJ, Pieterse AH, Smets EMA.

Patient Educ Couns. 2019 Jul 10. pii: S0738-3991(19)30284-8. doi: 10.1016/j.pec.2019.07.011. [Epub ahead of print]

PMID:
31349965
8.

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.

Bahjat M, de Wilde G, van Dam T, Maas C, Bloedjes T, Bende RJ, van Noesel CJM, Luijks DM, Eldering E, Kersten MJ, Guikema JEJ.

Cell Cycle. 2019 Sep;18(18):2307-2322. doi: 10.1080/15384101.2019.1646068. Epub 2019 Jul 26.

9.

Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group.

Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10.

PMID:
31290569
10.

Long-term effectiveness and cost-effectiveness of an 18-week supervised exercise program in patients treated with autologous stem cell transplantation: results from the EXIST study.

van Dongen JM, Persoon S, Jongeneel G, Bosmans JE, Kersten MJ, Brug J, Nollet F, Chinapaw MJM, Buffart LM.

J Cancer Surviv. 2019 Aug;13(4):558-569. doi: 10.1007/s11764-019-00775-9. Epub 2019 Jul 8.

11.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Beerenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2019 May 23. pii: haematol.2018.214122. doi: 10.3324/haematol.2018.214122. [Epub ahead of print]

12.

Effective Information Provision About the Side Effects of Treatment for Malignant Lymphoma: Protocol of a Randomized Controlled Trial Using Video Vignettes.

Labrie N, van Dulmen S, Kersten MJ, de Haes HJ, Pieterse AH, van Weert JC, van Spronsen DJ, Smets EM; INSTRUCT Group.

JMIR Res Protoc. 2019 May 2;8(5):e12453. doi: 10.2196/12453.

13.

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.

Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P.

Haematologica. 2019 Nov;104(11):2265-2273. doi: 10.3324/haematol.2018.205476. Epub 2019 Apr 4.

14.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S.

Haematologica. 2019 Nov;104(11):2274-2282. doi: 10.3324/haematol.2018.213900. Epub 2019 Mar 28.

15.

Return to work experiences of patients treated with stem cell transplantation for a hematologic malignancy.

Persoon S, Buffart LM, Chinapaw MJM, Nollet F, Frings-Dresen MH, Koning S, Kersten MJ, Tamminga SJ.

Support Care Cancer. 2019 Aug;27(8):2987-2997. doi: 10.1007/s00520-018-4596-0. Epub 2018 Dec 27.

16.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ann Oncol. 2019 May 1;30(5):860-862. doi: 10.1093/annonc/mdy466. No abstract available.

PMID:
30520968
17.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ.

Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. No abstract available.

18.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
19.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. doi: 10.1093/annonc/mdy322. No abstract available.

PMID:
30285219
20.

Developing a digital communication training tool on information-provision in oncology: uncovering learning needs and training preferences.

Stuij SM, Labrie NHM, van Dulmen S, Kersten MJ, Christoph N, Hulsman RL, Smets E; INSTRUCT project group.

BMC Med Educ. 2018 Sep 24;18(1):220. doi: 10.1186/s12909-018-1308-x.

21.

Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data.

Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM.

Br J Sports Med. 2019 Jul;53(13):812. doi: 10.1136/bjsports-2018-099191. Epub 2018 Sep 4.

PMID:
30181323
22.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270.

PMID:
29982402
23.

Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment.

Koens L, van de Ven PM, Hijmering NJ, Kersten MJ, Diepstra A, Chamuleau M, de Jong D.

Histopathology. 2018 Sep;73(3):473-482. doi: 10.1111/his.13647. Epub 2018 Jun 26.

PMID:
29758590
24.

Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls.

van Sandwijk MS, Al Arashi D, van de Hare FM, van der Torren JMR, Kersten MJ, Bijlsma JA, Ten Berge IJM, Bemelman FJ.

Nephrol Dial Transplant. 2019 May 1;34(5):833-838. doi: 10.1093/ndt/gfy103.

PMID:
29726909
25.

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ.

Lancet Haematol. 2018 Apr;5(4):e170-e180. doi: 10.1016/S2352-3026(18)30030-9. Epub 2018 Mar 14. Erratum in: Lancet Haematol. 2018 Jun;5(6):e240.

PMID:
29550382
26.

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP.

Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. No abstract available.

PMID:
29514783
27.

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ; HOVON Lunenburg Lymphoma Phase I/II Consortium.

Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x. No abstract available.

28.

Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature.

Nijland ML, Koens L, Pals ST, Berge IJMT, Bemelman FJ, Kersten MJ.

Haematologica. 2018 Mar;103(3):486-496. doi: 10.3324/haematol.2017.169987. Epub 2017 Dec 21.

29.

Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.

Ren Z, van Andel H, de Lau W, Hartholt RB, Maurice MM, Clevers H, Kersten MJ, Spaargaren M, Pals ST.

Blood. 2018 Mar 1;131(9):982-994. doi: 10.1182/blood-2017-07-797050. Epub 2017 Dec 6.

PMID:
29212806
30.

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.

Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ, Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H.

Ann Hematol. 2018 Feb;97(2):255-266. doi: 10.1007/s00277-017-3167-7. Epub 2017 Dec 6.

31.

High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy.

Vos JM, Notermans NC, D'Sa S, Lunn MP, van der Pol WL, Kraan W, Reilly MM, Chalker J, Gupta R, Kersten MJ, Pals ST, Minnema MC.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):1007-1009. doi: 10.1136/jnnp-2017-316689. Epub 2017 Oct 10. No abstract available.

PMID:
29018161
32.

Lessons learnt from a process evaluation of an exercise intervention in patients treated with autologous stem cell transplantation.

Persoon S, Chinapaw MJM, Buffart LM, Brug J, Kersten MJ, Nollet F.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12779. Epub 2017 Sep 27.

33.

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

Vos JM, Tsakmaklis N, Patterson CJ, Meid K, Castillo JJ, Brodsky P, Ganz T, Pals ST, Kersten MJ, Xu L, Yang G, Treon SP, Hunter ZR.

Haematologica. 2017 Nov;102(11):e452-e455. doi: 10.3324/haematol.2017.172627. Epub 2017 Aug 10. No abstract available.

34.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
35.

Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study.

Persoon S, ChinAPaw MJM, Buffart LM, Liu RDK, Wijermans P, Koene HR, Minnema MC, Lugtenburg PJ, Marijt EWA, Brug J, Nollet F, Kersten MJ.

PLoS One. 2017 Jul 20;12(7):e0181313. doi: 10.1371/journal.pone.0181313. eCollection 2017.

36.

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.

Franssen LE, Roeven MWH, Hobo W, Doorn R, Oostvogels R, Falkenburg JHF, van de Donk NW, Kester MGD, Fredrix H, Westinga K, Slaper-Cortenbach I, Spierings E, Kersten MJ, Dolstra H, Mutis T, Schaap N, Lokhorst HM.

Bone Marrow Transplant. 2017 Oct;52(10):1378-1383. doi: 10.1038/bmt.2017.118. Epub 2017 Jun 5.

PMID:
28581468
37.

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, Salles G, Klapper W, Pfreundschuh M, Jack A, Gascoyne RD, Natkunam Y, Advani R, Kimby E, Sander B, Sehn LH, Hagenbeek A, Raemaekers J, Gribben J, Kersten MJ, Ylstra B, Weller E, de Jong D.

Haematologica. 2017 Aug;102(8):1413-1423. doi: 10.3324/haematol.2017.165415. Epub 2017 Apr 14.

38.

Validation and Refinement of Prediction Models to Estimate Exercise Capacity in Cancer Survivors Using the Steep Ramp Test.

Stuiver MM, Kampshoff CS, Persoon S, Groen W, van Mechelen W, Chinapaw MJM, Brug J, Nollet F, Kersten MJ, Schep G, Buffart LM.

Arch Phys Med Rehabil. 2017 Nov;98(11):2167-2173. doi: 10.1016/j.apmr.2017.02.013. Epub 2017 Mar 18.

PMID:
28322759
39.

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.

D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP.

Br J Haematol. 2017 Mar;176(5):728-742. doi: 10.1111/bjh.14492. Epub 2017 Feb 15.

PMID:
28198999
40.

The landscape of new drugs in lymphoma.

Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J.

Nat Rev Clin Oncol. 2017 Jun;14(6):335-346. doi: 10.1038/nrclinonc.2016.205. Epub 2016 Dec 29. Review.

41.

Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.

van Andel H, Ren Z, Koopmans I, Joosten SP, Kocemba KA, de Lau W, Kersten MJ, de Bruin AM, Guikema JE, Clevers H, Spaargaren M, Pals ST.

Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):376-381. doi: 10.1073/pnas.1618650114. Epub 2016 Dec 27.

42.

Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs.

Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Lucia A, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J.

Cancer Treat Rev. 2017 Jan;52:91-104. doi: 10.1016/j.ctrv.2016.11.010. Epub 2016 Dec 5. Review.

43.

Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia.

Pals ST, Kersten MJ, Spaargaren M.

Best Pract Res Clin Haematol. 2016 Jun;29(2):161-168. doi: 10.1016/j.beha.2016.08.019. Epub 2016 Sep 7. Review.

PMID:
27825462
44.

FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?

Zijlstra JM, Burggraaff CN, Kersten MJ, Barrington SF; EHA Scientific Working Group on Lymphoma.

Haematologica. 2016 Nov;101(11):1279-1283. No abstract available.

45.

Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.

van Andel H, Kocemba KA, de Haan-Kramer A, Mellink CH, Piwowar M, Broijl A, van Duin M, Sonneveld P, Maurice MM, Kersten MJ, Spaargaren M, Pals ST.

Oncogene. 2017 Apr;36(15):2105-2115. doi: 10.1038/onc.2016.368. Epub 2016 Oct 24.

PMID:
27775078
46.

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP.

Haematologica. 2017 Jan;102(1):43-51. doi: 10.3324/haematol.2016.147728. Epub 2016 Oct 6.

47.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Sep;30(9):1963. doi: 10.1038/leu.2016.184. No abstract available.

PMID:
27600169
48.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.

Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC.

Hematol Oncol. 2017 Dec;35(4):497-503. doi: 10.1002/hon.2342. Epub 2016 Aug 17.

PMID:
27530779
49.

Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.

Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ.

Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan.

50.

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes.

Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, Meid K, Minnema MC, Kersten MJ, Treon SP, Castillo JJ.

Br J Haematol. 2016 Nov;175(4):623-630. doi: 10.1111/bjh.14279. Epub 2016 Jul 29.

PMID:
27468978

Supplemental Content

Loading ...
Support Center